Valneva SE (VALN)
NASDAQ: VALN · Real-Time Price · USD
5.50
-0.07 (-1.17%)
Nov 18, 2026, 9:30 AM EST - Market open
Valneva SE Market Cap
Valneva SE has a market cap or net worth of $528.39 million as of November 18, 2026. Its market cap has decreased by 30.66% in one year.
Market Cap
528.39M
Enterprise Value
626.10M
1-Year Change
-30.66%
Global Rank
n/a
Country Rank
n/a
Category
ChartMarket Cap Chart
Since the IPO on May 6, 2021, Valneva SE's market cap has decreased from $1.29B to $528.39M, a decrease of -59.12%. That is a compound annual growth rate of -14.91%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 18, 2026 | 528.39M | -29.94% |
| Dec 31, 2025 | 754.16M | 107.47% |
| Dec 31, 2024 | 363.50M | -49.80% |
| Dec 29, 2023 | 724.08M | -21.32% |
| Dec 30, 2022 | 920.30M | -68.57% |
| Dec 31, 2021 | 2.93B | 126.51% |
| May 6, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Orchestra BioMed Holdings | 570.61M |
| Electra Therapeutics | 554.86M |
| Capricor Therapeutics | 554.09M |
| Entera Bio | 541.57M |
| Zevra Therapeutics | 540.30M |
| Eupraxia Pharmaceuticals | 538.75M |
| REGENXBIO | 505.18M |
| Neurogene | 495.37M |